Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
Best practice resources for practitioners and commissioners.
Useful sources of information and advice for healthcare professionals, patients, parents and carers.
Summaries of evidence and advice on common health topics (CKS)
On NICE’s 25th anniversary, our partners and collaborators in the health care system discuss what the future holds for NICE.